Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
72.04
-1.19 (-1.63%)
At close: Feb 19, 2026, 4:00 PM EST
71.89
-0.15 (-0.21%)
After-hours: Feb 19, 2026, 6:49 PM EST
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$3,301,681
Profits / Employee
$749,147
Market Cap
8.50B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 673 |
| Madrigal Pharmaceuticals | 528 |
| Cytokinetics | 498 |
| Vaxcyte | 414 |
| Krystal Biotech | 295 |
HALO News
- 1 day ago - Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge - Seeking Alpha
- 1 day ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE - PRNewsWire
- 9 days ago - Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - PRNewsWire
- 16 days ago - Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha
- 22 days ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 22 days ago - Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance - PRNewsWire
- 4 weeks ago - Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - PRNewsWire